Strut Health Ideal Patient Profile: Who Gets the Most From This Telehealth Platform

What Strut Health Actually Is

Strut Health operates as an asynchronous telehealth clinic. Patients complete an online intake form, upload photos where relevant (for hair or skin), and a licensed physician reviews the case before issuing any prescription. There is no mandatory live video call, which lowers friction but also means the physician-patient relationship is shallower than in a traditional clinic.

Treatments are dispensed through partner pharmacies and shipped directly to the patient. This model fits squarely into the broader cash-pay telehealth category that has grown significantly since 2020, though it carries the same caveats: no lab-result integration from outside providers, limited follow-up depth, and full cost borne by the patient.

The Legal and Regulatory Framework

Strut Health prescribers hold state medical licenses. Compounded medications supplied through the platform must meet USP Chapter 795 (non-sterile) or USP Chapter 797 (sterile) standards as enforced by state boards of pharmacy and overseen at the federal level by the FDA's guidance on compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. The FDA's current compounding framework is published at fda.gov.

Patients should confirm that any pharmacy dispensing their compounded medication holds an active state pharmacy license and, for sterile preparations, accreditation from a body such as PCAB.

What "Asynchronous" Means in Practice

Asynchronous review means the physician reads your intake, may send follow-up questions via the platform's messaging system, and approves or declines the prescription without a scheduled call. The American Telemedicine Association notes that asynchronous (store-and-forward) models are appropriate for conditions where photo documentation and standardized questionnaires capture sufficient clinical information. ATA clinical guidelines are available at the National Library of Medicine.

Hair loss and ED fit that criterion reasonably well. Complex metabolic conditions may not.

Androgenetic Alopecia: The Strongest Clinical Case for Strut Health

Men with pattern hair loss represent Strut Health's clearest best-fit patient group. Androgenetic alopecia (AGA) affects approximately 50% of men by age 50, according to the American Academy of Dermatology. Prevalence data are summarized in this NIH review.

Finasteride and Minoxidil: The Evidence Base

The platform's hair-loss formulations center on finasteride and minoxidil, both of which have decades of level-one evidence behind them.

A 5-year randomized controlled trial published in the Journal of the American Academy of Dermatology (N=1,553) found that finasteride 1 mg daily produced a 48% increase in hair count from baseline at 5 years versus progressive loss in the placebo group. PubMed PMID 12196747.

Topical minoxidil 5% applied twice daily produced statistically significant increases in non-vellus hair count compared with placebo in the key trial supporting FDA approval. FDA labeling history is accessible via accessdata.fda.gov.

Strut Health offers combination topical formulas that pair finasteride with minoxidil in a single application, which may improve adherence. A 2021 randomized trial in Dermatology and Therapy (N=90) found that a topical finasteride-minoxidil combination produced superior hair-count outcomes at 24 weeks compared with either agent alone, with lower systemic finasteride exposure than oral dosing. PubMed PMID 34427890.

Who Qualifies for Hair-Loss Treatment Through Strut

The ideal hair-loss patient on this platform is a man with mild-to-moderate AGA (Norwood scale I through IV), no history of prostate cancer, normal baseline sexual function, and a preference for a topical rather than oral route to minimize systemic DHT suppression. Patients with Norwood V or higher may see limited benefit from any medical therapy and should consult a hair-transplant surgeon before starting long-term pharmacy spending.

Sexual Side-Effect Risk: What the Data Say

Oral finasteride 1 mg carries a labeled risk of sexual adverse effects. The prescribing information lists decreased libido, erectile dysfunction, and ejaculation disorder in 1.8 to 3.8% of men versus 1.3% placebo. FDA prescribing information via accessdata.fda.gov. Topical finasteride appears to lower systemic DHT suppression and may reduce this risk, though large-scale head-to-head safety data are still accumulating.

Erectile Dysfunction: Appropriate Use and Limits

ED is the second-largest treatment category on the platform. Phosphodiesterase type-5 inhibitors (PDE5i), sildenafil and tadalafil, are the first-line pharmacological treatment per the American Urological Association guideline. AUA ED guideline summary at auanet.org; supporting systematic review at PubMed PMID 16287501.

Which Men Fit This Category

A Strut Health ED prescription fits men who have already been evaluated in person at least once, have a known cause (psychogenic or mild vasculogenic), take no nitrate medications, and want ongoing supply without repeated in-office visits. The asynchronous intake asks about nitrate use and cardiovascular history; patients who disclose nitrate use should be declined, consistent with the absolute contraindication established in the 1998 sildenafil approval. FDA sildenafil label via accessdata.fda.gov.

When This Platform Is Insufficient

ED can be the presenting symptom of undiagnosed cardiovascular disease, hypogonadism, or diabetes. The Princeton III Consensus recommends cardiac risk stratification before PDE5i prescribing in men with intermediate or high cardiovascular risk. Princeton III published at PubMed PMID 23551463. An asynchronous intake cannot replicate that evaluation. Men with unexplained new-onset ED, particularly those over 50, benefit from an in-person workup before relying on a telehealth-only prescription pathway.

Weight Management and GLP-1 Medications

Strut Health has expanded into weight management, including compounded semaglutide during periods when the branded product (Ozempic, Wegovy) was on the FDA shortage list. The FDA removed semaglutide from the drug shortage list in 2024 and issued guidance restricting 503A pharmacy compounding of semaglutide, which materially affects what compounding-dependent platforms may legally dispense. FDA shortage and compounding guidance at fda.gov.

Clinical Evidence for Semaglutide

The STEP-1 trial (N=1,961) showed that semaglutide 2.4 mg subcutaneously once weekly produced a mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001). STEP-1 at NEJM: DOI 10.1056/NEJMoa2032583. The STEP-5 trial (N=304) demonstrated maintained weight loss over 104 weeks. PubMed PMID 35441470.

Patient Selection for GLP-1 Through Telehealth

The Endocrine Society clinical practice guideline recommends pharmacological treatment for obesity in adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity. Endocrine Society guideline at endocrine.org. Patients who meet those criteria, have had a recent metabolic panel and HbA1c, understand the injection technique, and are comfortable managing GI side effects without weekly nurse check-ins may benefit from a telehealth prescribing model.

Patients with a personal or family history of medullary thyroid carcinoma or MEN2 are contraindicated per FDA labeling and should not use this pathway. FDA Wegovy label at accessdata.fda.gov.

The Compounding Concern

Patients seeking compounded semaglutide after the shortage removal should understand that the legal field has tightened. The FDA's March 2025 compliance policy states that 503A pharmacies may no longer compound semaglutide for individual patients simply because a branded product is unavailable. Platforms that continue offering compounded semaglutide under those conditions may be operating outside current FDA guidance. Patients should ask their Strut Health prescriber directly whether the formulation being dispensed is a compounded copy or an FDA-approved branded product.

Peptides: The Least-Regulated Category

Strut Health lists peptide treatments including, at various times, sermorelin and ipamorelin (growth hormone secretagogues). These sit in a complex regulatory space.

Regulatory Status of Peptide Compounds

The FDA classifies sermorelin acetate as an approved drug (FDA NDA 019764). FDA records via accessdata.fda.gov. However, many other peptides marketed through telehealth platforms do not hold NDA approval and may be treated as bulk drug substances. The FDA's 503A bulks list and its Category 1/2/3 evaluation framework govern which peptides compounding pharmacies may lawfully use. FDA bulks list guidance at fda.gov.

Who Should Be Cautious With Peptide Prescriptions

Any patient considering peptide therapy through an asynchronous telehealth platform should request the specific FDA regulatory status of each peptide before purchase. Long-term safety data for many peptide compounds come from small studies or animal models. A systematic review of growth hormone secretagogue research in humans noted that most trials involve fewer than 100 participants and follow-up under 6 months. PubMed PMID 29992192. Patients with active malignancy, acromegaly, or untreated pituitary disease should not use these agents outside a formal endocrinology practice.

Is Strut Health Legit? An Independent Assessment

The following four-point legitimacy framework applies to any cash-pay telehealth platform and can guide patient evaluation of Strut Health specifically.

1. Prescriber licensure. Strut Health physicians hold active state licenses verifiable through state medical board databases. Patients can confirm this at their state medical board website. The Federation of State Medical Boards maintains a consolidated lookup. FSMB DocInfo tool referenced at fsmb.org; prescriber-verification guidance at ncbi.nlm.nih.gov/books/NBK573560/.

2. Pharmacy compliance. Compounding pharmacies must register with the FDA and hold state licensure. Patients should ask which pharmacy fills their prescription and verify its license. The National Association of Boards of Pharmacy maintains a Pharmacy Verifier tool. NABP guidance referenced in FDA compounding oversight documents at fda.gov.

3. Informed-consent quality. Legitimate platforms disclose contraindications, side effects, and the limits of asynchronous care before prescribing. The intake questionnaire should ask about concurrent medications, prior diagnoses, and relevant lab values.

4. Refusal rate. A platform that approves every intake without question is not practicing medicine. Strut Health's asynchronous model does allow physicians to decline or request additional information; patients declined for clinical reasons should interpret that as a safety feature, not a flaw.

The American Telemedicine Association's 2023 practice standards state that "the standard of care does not change simply because the care is delivered virtually." ATA standards cited in PubMed review PMID 36702104.

Strut Health vs. Alternatives: A Comparative Look

Several platforms occupy similar space. The comparison below is clinically focused, not promotional.

Hair Loss Alternatives

Keeps and Hims offer finasteride and minoxidil through comparable asynchronous models at similar price points. A 2022 analysis in JAMA Dermatology found no significant difference in patient-reported outcomes between in-person and telehealth finasteride prescribing at 12 months, suggesting the channel matters less than adherence. PubMed PMID 35080596. Strut's differentiation is primarily its combination compounded topicals, which may reduce pill burden for patients averse to oral finasteride.

ED Alternatives

Roman (Ro), Hims, and BlueChamp offer similar PDE5i access. Cost per pill for generic sildenafil has dropped substantially since patent expiration; GoodRx pricing for generic tadalafil 5 mg daily can fall below $15/month at retail pharmacies with a standard in-office prescription, which is worth considering before enrolling in any subscription model.

Weight-Management Alternatives

Found, Calibrate, and direct-to-patient branded-drug programs (Eli Lilly's LillyDirect, Novo Nordisk's NovoCare) each have different formulary access and monitoring intensity. Calibrate requires lab work and regular video visits, which provides more clinical oversight. Strut Health's model is lower-friction but also lower-monitoring.

When to Choose an In-Person Clinic Instead

Patients with multiple comorbidities, those taking more than three prescription medications, men over 60 with new symptoms, and anyone who has been told by a prior physician that a condition needs specialist follow-up should start with in-person care. Telehealth platforms supplement but do not replace the primary care relationship.

Cost Breakdown and What Patients Actually Pay

Strut Health charges no consultation fee; revenue comes from the prescription itself. Approximate monthly costs based on publicly posted pricing as of mid-2025:

• Topical finasteride-minoxidil combination: $55, $90/month
• Oral finasteride 1 mg: $35, $55/month
• Sildenafil (compounded or branded): $50, $130/month depending on dose and quantity
• Tadalafil daily: $55, $95/month
• Semaglutide (where available and legally permissible): $150, $350/month
• Sermorelin: $120, $200/month

No insurance reimbursement is available. HSA/FSA eligibility for prescription costs generally applies but patients should confirm with their plan administrator. The IRS defines eligible medical expenses in Publication 502. IRS Publication 502 referenced at irs.gov; health-spending-account eligibility discussed at cdc.gov/niosh guidance page.

For men whose hair-loss or ED prescriptions would cost less than $30/month at a retail pharmacy with a local doctor's prescription, the convenience premium of a telehealth platform may not justify the added cost.

The Ideal Strut Health Patient: A Clinical Summary

The patient most likely to benefit from Strut Health meets all of the following criteria:

• Male, age 20 to 55, otherwise healthy with no complex comorbidities
• Diagnosed or self-identified condition in one of the platform's core areas (AGA, ED, mild obesity)
• Comfortable with online-only interaction and absence of live video
• Able to pay out-of-pocket without financial hardship
• Has had at least one in-person evaluation in the past two years that ruled out a serious underlying cause
• Understands that compounded medications are not FDA-approved finished drug products

Patients who fall outside these parameters are not well-served by asynchronous telehealth and should seek in-person or hybrid-model care. The USPSTF recommends that primary care clinicians offer or refer to intensive, multicomponent behavioral weight-loss interventions for adults with obesity, a standard that a brief online intake does not fulfill. USPSTF weight-loss recommendation at uspreventiveservicestaskforce.org; full statement at PubMed PMID 30326213.

Men with AGA who have been on finasteride for 12 months without measurable hair-count response should consult a board-certified dermatologist before continuing pharmacy spend, as non-response at 12 months predicts non-response at 24 months with approximately 80% accuracy per a 2014 retrospective cohort study (N=174). PubMed PMID 24527481.